Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Consumer Cos Climb On Reopening Optimism -- Consumer Roundup

04/16/2021 | 05:19pm EDT

Shares of retailers and other consumer companies rose sharply amid growing optimism about the U.S. reopening.

"The Johnson & Johnson clot issue is delaying a key single dose and easily stored vaccine solution," said Edward Moya, senior market analyst at foreign exchange brokerage OANDA Group, in a note to clients.

"An abundance of caution could mean we lose a week or two with the J&J vaccine, with some fearing that it will fuel greater vaccine hesitancy given the recent concerns with the AstraZeneca one."

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

04-16-21 1718ET

All news about ASTRAZENECA PLC
01:48pEU Tepid on Biden Call to Waive Intellectual Property Rights for Covid-19 Vac..
DJ
04:55aASTRAZENECA  : Sri Lanka approves Pfizer COVID vaccine for emergency use
RE
04:01aWho have provinces pegged to receive COVID-19 vaccines in the coming weeks?
AQ
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
DJ
05/07ASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
RE
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
DJ
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
DJ
05/07MARKET CHATTER : WHO's Director General Calls for Countries to Support Waiving C..
MT
05/07U.S. Support for Patent Waiver Unlikely to Cost Covid-19 Vaccine Makers in Sh..
DJ
05/07How the U.S. locked up vaccine materials other nations urgently need
RE
More news
Financials (USD)
Sales 2021 30 843 M - -
Net income 2021 4 552 M - -
Net Debt 2021 11 038 M - -
P/E ratio 2021 29,7x
Yield 2021 2,64%
Capitalization 142 B 142 B -
EV / Sales 2021 4,96x
EV / Sales 2022 4,42x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 130,07 $
Last Close Price 108,20 $
Spread / Highest target 53,4%
Spread / Average Target 20,2%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC5.61%142 034
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
PFIZER, INC.6.47%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539